Navigation Links
Substance in Medical Technology

SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts

... Youth Sports Institute and experts in psychiatry, substance abuse, toxicology, kinesiology, clinical ... Philadelphia, PA, Associate Director, Center for substance Abuse Research, University of Maryland, College ... Philadelphia, PA Associate Director, Center for substance Abuse Research, University of Maryland, College ...

White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product

... Where and What to Test: From Purified Bulk Drug substance to Sterile Liquid Final Drug Product, " ... life cycle: going from the purified bulk drug substance ("PBDS") to the sterile final drug product ... Where and What to Test: From Purified Bulk Drug substance to Sterile Liquid Final Drug Product, " visit: ...

Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults

... age 17 and over. Vimpat(R) has been designated as a Schedule V controlled substance by U.S. regulators. In August 2008, the European Commission approved ... not feasible. Contraindications: Hypersensitivity to the active substance or to peanuts or soya or to any of the excipients; known second- or ...

DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms

... comments, "This opens the door to a completely novel way of supplying drug substance for clinical trials and for market needs. The XD(R) process increases the ... reduced by applying this technology. Now, up to several kilograms of drug substance can be manufactured in a single batch from small disposable bioreactors." ...

Heavy Marijuana Use May Damage Developing Brain in Teens, Young Adults

... connect different brain regions. "Our results suggest that early-onset substance use may alter the development of white matter circuits, especially those ... adolescent brain may be especially vulnerable to risky behaviors such as substance abuse, because of crucial neural development that occurs during those ...

Novel Compound Shows Promise for Treatment of Alcoholism

... supported by the State of California for Medical Research on Alcohol and substance Abuse and Department of Defense. Southern Research operates a successful ... academic centers for the study of the biological basis of alcohol and substance abuse. Gallo Center discoveries of potential molecular targets for the ...

GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

... are associated with CINV. The central pathway is activated by substance P and mediated by neurokinin (NK-1) receptors that are highly concentrated ... primarily in the gut.(7) NK-1 receptor antagonists like casopitant block substance P from binding to receptors within the brain and have the potential to add ...

ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells

... P is an analog of the naturally occurring human neuropeptide substance P, which can be found throughout the body, including in the airways of ... homeland security bioterrorism threats. Homspera(TM) is derived from substance P, a naturally occurring peptide immunomodulator and homeostatic compound ...

ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.

... is an analog of the naturally occurring human neuropeptide substance P, which can be found throughout the body, including in the airways of ... multiple homeland security bioterrorism threats. Homspera is derived from substance P, a naturally occurring peptide immunomodulator and homeostatic compound ...

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

... a once-daily, extended release formulation of guanfacine, designed to provide steady delivery of drug throughout the day. INTUNIV is not a controlled substance and has no known potential for abuse or dependence. Guanfacine, the active ingredient in INTUNIV, is thought to work directly by binding ...

R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023

... drug for glaucoma and ocular hypertension and has been marketed in Japan since 1994. R-Tech Ueno was the first in the world to take advantage of the substance "prostone" in the development of Rescula(R) eyedrop 0.12%. Prostone was discovered in 1980's by Dr. Ryuji Ueno, the founder of the company. ...

PTSD Associated With Higher Alzheimer's/Dementia Risk; Moderate Alcohol Consumption May Lower it

... compared to veterans without PTSD (HR = 1.8, 95% CI 1.7-1.9). Results were similar when they excluded those with a history of traumatic brain injury, substance abuse or depression. "It is critical to follow patients with PTSD, and evaluate them early for dementia," Yaffe said. "Further research is ...

Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians

... Albany Medical College , N.Y. In "Opioid Metabolism," he writes that approximately 10 percent to 20 percent of physicians will develop a substance abuse problem during their career, a rate similar to or exceeding the general population. For anesthesiologists, according to Drs. Oreskovich and ...

June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates

... oak: Contact with these plants causes red, swollen skin, blisters and severe itching within days or weeks of exposure. These plants produce an oily substance called urushiol, which causes an allergic reaction in most people. Urushiol can stick to almost anything, including clothes, pet fur, and even ...

ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402

... them in collaboration with partners including Genentech, Roche and ThromboGenics. These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abello, Bayer HealthCare, ...

Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries

... launched on a preliminary basis in Belgium. The effective commercial launch will take place in a couple of months. Salvacyl(R) contains the active substance triptorelin, a gonadotropin releasing hormone (GnRH) agonist analogue. The product will be prescribed for the reversible reduction of serum ...

Scottsdale Facility to Be First in U.S. to Showcase True REST Technology

... variety of other behavioral and mental health disorders. A University of Arizona study examined chamber REST as a relapse prevention technique for substance abusers enrolled in traditional outpatient treatment programs. At the end of four years of follow-up, 43 percent remained continuously sober and ...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... may cause an increase in the risk of malignancies. About IL-6 IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much. When approved, ACTEMRA will be the first and only ...

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

... Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

... may cause an increase in the risk of malignancies. About IL-6 IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much. When approved, ACTEMRA will be the first and only ...

Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms

... of ADHD in children and adolescents. In clinical trials, INTUNIV demonstrated significant reduction in ADHD symptoms. INTUNIV is not a controlled substance and has no known mechanism for abuse or dependence. Guanfacine, the active ingredient in INTUNIV, is thought to work directly by binding ...

ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services

... performance measures in place for hospitals which are accredited by The Joint Commission: Admission screening for violence risk, substance use, psychological trauma history and patient strengths Hours of physical restraint use Hours of seclusion use Patients ...

China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit

... SCD and his fundamental research has led to several breakthroughs. In 2008, Prof. Yang and his research team found that the concentration of a substance called "MicroRNA-1" in human blood has positive correlation with the occurrence of SCD. After detailed clinical studies involving many samples, Prof. ...

New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer

... cancer, skin cancer, and others. The medicines represent many cutting-edge approaches, including a drug that delivers a synthetic version of a substance derived from scorpions directly to brain tumor cells; a number of cancer vaccines; medicines that target and kill specific cancer cells; and ...

BARC Central Laboratory Joins Alzheimer's Association Research Roundtable

... meetings, with particular focus on the evolution of biochemical biomarkers as prognostic and diagnostic indicators. A biomarker is a substance or characteristic that can be objectively measured and evaluated as an indicator of normal body processes, disease processes, or the body's ...

Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories

... 85 percent of people, at some point in their lives. The disorder is thought to be caused by multiple factors. Overproduction of sebum, a normal oily substance on the skin surface, combined with dead skin cells that are abnormally shed from the hair follicle, lead to plugging of the follicle. This allows ...

Got Pain?

... professor and chairman, Department of Orthopaedics, SUNY at Stony Brook School of Medicine, "injection therapy, such as Clostridial collagenase (a substance intended to reduce the collagen buildup in the palm and disrupt the contracted cord) has now shown promising results for patients with Dupuytren's ...

Aching Back? Cholesterol Medication Might Help

... Hospital. In one study, the researchers removed nucleus pulposus tissues from six human patients. (Nucleus pulposus is the jelly-like substance in the middle of the spinal disc.) The patients, ages 23 to 29, were undergoing surgery for herniated lumbar discs. Researchers then isolated the ...

Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997

... Not blinded. ------------------------------------------------------------------------- Product Development Status Drug substance and drug product are manufactured to GMP standards. ...

ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)

... them in collaboration with partners including Genentech, Roche and ThromboGenics. These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abello, Bayer HealthCare, ...

Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial

... exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents ...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

... cause an increase in the risk of malignancies. About IL-6 IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much. When approved, ACTEMRA will be the ...

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients

... ACTEMRA, may cause an increase in the risk of malignancies. About IL-6 IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much. When approved, ACTEMRA will be the first and ...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

... ACTEMRA, may cause an increase in the risk of malignancies. About IL-6 IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much. When approved, ACTEMRA will be the first and only ...

Burcon announces GRAS status for Puratein(R) & Supertein(TM)

... GRAS notification is a voluntary procedure whereby a company informs the FDA of its determination that the use of a substance is GRAS. A substance is GRAS Notified when, after reviewing the GRAS notification, the FDA responds with a no-objection letter if it is satisfied with the submission. It ...

AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform

... of quality of life. Parkinson's is caused by degeneration and death of nerve cells in a specific part of the brain. These cells produce dopamine, a substance necessary for communication between nerve cells involved in the coordination of movement. Current therapies are limited to treatment of symptoms. ...

Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

... al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain. 2006; 22:667-676. 6. substance Abuse and Mental Health Services Administration. (2007). Results from the 2006 National Survey on Drug Use and Health: National Findings (Office of ...

Cytopia Commences Second Phase II Study in Brain Cancer

... and tumor apoptosis, and pharmacokinetic analyses. Blinding status Not blinded. Product development Drug substance and drug product are manufactured to status GMP standards. Treatment method Route 24 hour intravenous infusion ...

Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss

... which is currently at epidemic proportions in the U.S. In addition to development of CPP-109 for treatment of cocaine, methamphetamine and other substance addictions, the compound appears to provide a platform for multiple indications, including as a potential treatment for obsessive compulsive ...

Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's

... Alzheimer's Disease (ICAD 2008) in Chicago bring us closer to that goal of early detection by describing advances in biomarkers. A biomarker is a substance or characteristic that can be objectively measured and evaluated as an indicator of normal body processes, disease processes, or the body's ...
Other Contents
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season may ... Acuity Market Intelligence reports that the long anticipated floodgates ... that intensifying demand for smart phones, tablets, and wearable ... market of 2.5 billion users with nearly 4.8 billion ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Four years since the ... – which coincided with the marriage of Avasa & Matthew Love ... ROAD, which is scheduled for release through White Swan Records on ... that there is a sacred path available to all of us ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
Other TagsOther Tags